"I'm incredibly honored to be recognized by such a distinguished group of scientists," said Dr. Gabelnick. "The scientific community of India has made great strides in reproductive health and microbicide development, but I feel that we have so much more to accomplish. I hope to have increased support, particularly in the area of microbicide development, to continue funding this important area."
This year's conference focuses on new strategies such as microbicides to halt the incidence of HIV infections. India is now second to South Africa in the number of overall people living with AIDS and the epidemic continues to shift towards women and young people with nearly half of people living with AIDS being women.
Dr. Gabelnick joined CONRAD at its inception in 1986 and is also a professor in the Department of Obstetrics and Gynecology at the Eastern Virginia Medical School. He has served on panels of the National Research Council, NIH and WHO and currently serves as President of the Society for the Advancement of Reproductive Care.
CONRAD is currently conducting Phase III trials of Ushercell, a microbicide consisting of cellulose sulfate, which will evaluate its effectiveness for the prevention of HIV infection. Uganda, Benin, and South Africa are the first of six locations to be involved in the trial; other sites include Burkina Faso and two centers in India, including Chennai and Bangalore.
The Indian Council of Medical Research of New Delhi, India and CONRAD have signed a "Memorandum of Understanding" on cooperation in microbicide research. The principal objective of the a
'"/>
Contact: annette larkin
annettelarkin@rationalpr.com
202-429-4929
CONRAD
20-Oct-2005